Evidence map›Paper›PMID 31401418›Full record

ArticleJournal of neuroimmunology2019

Perturbations in neuroinflammatory pathways are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors.

Christine Miaskowski, Kimberly Topp, Yvette P Conley, Steven M Paul, Michelle Melisko, Mark Schumacher, Margaret Chesney, Gary Abrams, Jon D Levine, Kord M Kober

Open access · bronzeAbstract read
In one paragraph

Article in Journal of neuroimmunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Paclitaxel triggers molecular and cellular changes in the choroid plexus.Frontiers in pain research (Lausanne, Switzerland) · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Christine MiaskowskiSchool of Nursing, University of California, San Francisco, CA, United States of America.
Kimberly ToppSchool of Medicine, University of California, San Francisco, CA, United States of America.
Yvette P ConleySchool of Nursing, University of Pittsburgh, Pittsburgh, PA, United States of America.
Steven M PaulSchool of Nursing, University of California, San Francisco, CA, United States of America.
Michelle MeliskoSchool of Medicine, University of California, San Francisco, CA, United States of America.
Mark SchumacherSchool of Medicine, University of California, San Francisco, CA, United States of America.
Margaret ChesneySchool of Medicine, University of California, San Francisco, CA, United States of America.
Gary AbramsSchool of Medicine, University of California, San Francisco, CA, United States of America.
Jon D LevineSchool of Medicine, University of California, San Francisco, CA, United States of America.
Kord M KoberSchool of Nursing, University of California, San Francisco, CA, United States of America. Electronic address: kord.kober@ucsf.edu.
University of California, San Francisco · USUniversity of Pittsburgh · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Characterization of and Treatment for Chemotherapy NeuropathyR01CA151692 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MIASKOWSKI, CHRISTINE A. · 2011 to 2015
$6.4M
Advancing the Science of Symptom Management in Oncology PatientsK05CA168960 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MIASKOWSKI, CHRISTINE A. · 2013 to 2017
$453k
NCATS NIH HHS UL1 TR000004NCI NIH HHS K05 CA168960NCI NIH HHS R01 CA151692
6 · The paper itself

Abstract

Paclitaxel is a common chemotherapy drug associated with the development of chronic paclitaxel-induced peripheral neuropathy (PIPN). PIPN is associated with neuroinflammatory mechanisms in pre-clinical studies. Here, we evaluated for differential gene expression (DGE) in peripheral blood between breast cancer survivors with and without PIPN and for neuroinflammatory (NI) related signaling pathways and whole-transcriptome profiles from other experiments. Pathway impact analysis identified 8 perturbed NI related pathways. Expression profile analysis found 15 experiments having similar whole-transcriptome profiles of DGE related to neuroinflammation and PIPN. These findings suggest that perturbations in pathways associated with neuroinflammation are found in cancer survivors with PIPN.

Indexed as

Antineoplastic Agents, PhytogenicBreast NeoplasmsCancer SurvivorsFemaleHumansInflammationPaclitaxelPeripheral Nervous System DiseasesTranscriptomeAntineoplastic Agents, PhytogenicPaclitaxelBreast cancerChemokinesCytokinesDifferential gene expressionNeuroinflammationNeuropathyPaclitaxelPathway analysisSurvivorTaxanes

Identifiers

PMID31401418
PMCPMC6788784
OpenAlexW2966437865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.